Qual é o preço para Freeline Therapeutics Holdings plc (FRLN)

O preço para Freeline Therapeutics Holdings plc (FRLN) é $6.48

Qual é a capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN)

A capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN) é $15.41M

Freeline Therapeutics Holdings plc (FRLN) Rendimento de Dividendos

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Ano	Rendimento de Dividendos	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rendimento de Dividendos

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rendimento de Dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH
UCB S.A. UCB.BR	0.48%	BE

Empresa

Rendimento de Dividendos

País